Page last updated: 2024-09-05

razaxaban and ticlopidine

razaxaban has been researched along with ticlopidine in 1 studies

Compound Research Comparison

Studies
(razaxaban)
Trials
(razaxaban)
Recent Studies (post-2010)
(razaxaban)
Studies
(ticlopidine)
Trials
(ticlopidine)
Recent Studies (post-2010) (ticlopidine)
200210,2891,8934,671

Protein Interaction Comparison

ProteinTaxonomyrazaxaban (IC50)ticlopidine (IC50)
Alpha-2A adrenergic receptorHomo sapiens (human)0.382
Cytochrome P450 2D6Homo sapiens (human)6.2928
Alpha-2B adrenergic receptorHomo sapiens (human)0.304
Alpha-2C adrenergic receptorHomo sapiens (human)1.175
Cytochrome P450 2B6Homo sapiens (human)0.405
Cytochrome P450 2C19Homo sapiens (human)0.6678
Sigma non-opioid intracellular receptor 1Homo sapiens (human)0.426

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Crain, EJ; Knabb, RM; Lam, PY; Quan, ML; Watson, CA; Wexler, RR; Wong, PC1

Other Studies

1 other study(ies) available for razaxaban and ticlopidine

ArticleYear
Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits.
    Journal of thrombosis and thrombolysis, 2007, Volume: 24, Issue:1

    Topics: Animals; Aspirin; Blood Coagulation; Clopidogrel; Disease Models, Animal; Drug Therapy, Combination; Factor Xa; Fibrinolytic Agents; Hemorrhage; Hemostasis; Isoxazoles; Male; Platelet Aggregation; Pyrazoles; Rabbits; Thrombosis; Ticlopidine

2007